• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.

作者信息

Abuelgasim Khadega A, Alzahrani Mohsen, Alsharhan Yousef, Khairi Moataz, Hommady Mohammed, Gmati Giamal, Salama Hind, Ali Osama, Alahmari Bader, Masuadi Emad M, Alaskar Ahmed, Alhejazi Ayman, Damlaj Moussab

机构信息

King Abdulla International Medical Research Center, Riyadh, Saudi Arabia.

King Abdulaziz Medical City, Department of Oncology, Riyadh, Saudi Arabia.

出版信息

Bone Marrow Transplant. 2019 Jul;54(7):1168-1172. doi: 10.1038/s41409-019-0454-z. Epub 2019 Jan 30.

DOI:10.1038/s41409-019-0454-z
PMID:30700792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6760548/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6836/6760548/3be1ab4da785/41409_2019_454_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6836/6760548/3be1ab4da785/41409_2019_454_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6836/6760548/3be1ab4da785/41409_2019_454_Fig1_HTML.jpg

相似文献

1
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.用本妥昔单抗联合异环磷酰胺、吉西他滨和长春瑞滨进行化学免疫疗法，对复发或难治性经典型霍奇金淋巴瘤具有高度活性。
Bone Marrow Transplant. 2019 Jul;54(7):1168-1172. doi: 10.1038/s41409-019-0454-z. Epub 2019 Jan 30.
2
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.异环磷酰胺、吉西他滨和长春瑞滨是一种有效的挽救治疗方案，在复发或难治性小儿霍奇金淋巴瘤中具有极好的干细胞动员作用。
Pediatr Blood Cancer. 2020 Apr;67(4):e28167. doi: 10.1002/pbc.28167. Epub 2020 Jan 11.
3
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星作为二线治疗复发或难治性经典型霍奇金淋巴瘤的 II 期临床试验。
J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25.
4
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.达雷妥尤单抗联合异环磷酰胺、卡铂和依托泊苷治疗二线复发或难治性经典型霍奇金淋巴瘤：一项单中心、1/2 期研究。
Lancet Haematol. 2021 Aug;8(8):e562-e571. doi: 10.1016/S2352-3026(21)00170-8.
5
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.帕博利珠单抗对比本妥昔单抗维布妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤（KEYNOTE-204）：一项多中心、随机、开放标签、3 期研究的中期分析。
Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12.
6
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.难治性/复发性霍奇金淋巴瘤的串联大剂量化疗及自体干细胞移植：一项单中心前瞻性研究
Am J Hematol. 2007 Feb;82(2):122-7. doi: 10.1002/ajh.20790.
7
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.本妥昔单抗联合地塞米松、大剂量阿糖胞苷和顺铂作为复发/难治性经典型霍奇金淋巴瘤挽救治疗的Ⅰ期剂量递增研究：HOVON/LLPC移植BRAVE研究
Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31.
8
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.吉西他滨、长春瑞滨、聚乙二醇脂质体阿霉素和布伦妥昔单抗序贯联合作为复发或难治性霍奇金淋巴瘤移植前的桥接方案。
Haematologica. 2015 Jul;100(7):e269-71. doi: 10.3324/haematol.2015.124784. Epub 2015 Apr 3.
9
FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.采用含维布妥昔单抗的氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）适应性序贯治疗及强化异环磷酰胺、卡铂和依托泊苷（ICE）方案，随后进行自体干细胞移植治疗复发难治性霍奇金淋巴瘤。
Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 6):7.
10
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.异环磷酰胺、吉西他滨和长春瑞滨：一种用于难治性和复发性霍奇金淋巴瘤的新诱导方案。
Haematologica. 2007 Jan;92(1):35-41. doi: 10.3324/haematol.10661.

引用本文的文献

1
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.儿童、青少年和青年复发性霍奇金淋巴瘤的无移植治疗方法：一项非随机临床试验
JAMA Oncol. 2025 Mar 1;11(3):249-257. doi: 10.1001/jamaoncol.2024.5627.
2
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.超越化疗：淋巴增殖性疾病治疗的现状与未来展望
Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.
3
The role of transplantation in Hodgkin lymphoma.

本文引用的文献

1
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
2
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
3
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
移植在霍奇金淋巴瘤中的作用。
Front Oncol. 2023 Jan 26;12:1054314. doi: 10.3389/fonc.2022.1054314. eCollection 2022.
4
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.纳武单抗和本妥昔单抗联合或不联合苯达莫司汀治疗儿童、青少年和年轻成人复发/难治性霍奇金淋巴瘤。
Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118.
5
Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.本妥昔单抗和纳武单抗治疗难治性或复发性霍奇金淋巴瘤的疗效：一项系统评价。
Cureus. 2022 Mar 24;14(3):e23452. doi: 10.7759/cureus.23452. eCollection 2022 Mar.
6
Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.复发/难治性霍奇金淋巴瘤患者中 Brentuximab Vedotin 与帕博利珠单抗联合治疗：单中心回顾性分析
Cancers (Basel). 2022 Feb 15;14(4):982. doi: 10.3390/cancers14040982.
7
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.霍奇金淋巴瘤的一线挽救治疗选择：传统化疗与新型药物。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):240-246. doi: 10.1182/hematology.2021000311.
8
Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.在本妥昔单抗时代，复发难治性经典型霍奇金淋巴瘤患者在移植前需要多种挽救方案，仍有显著缓解情况。
Leuk Res Rep. 2021 Oct 21;16:100276. doi: 10.1016/j.lrr.2021.100276. eCollection 2021.
9
Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.霍奇金淋巴瘤的挽救治疗：当前治疗方案及结果综述
J Blood Med. 2020 Oct 27;11:389-403. doi: 10.2147/JBM.S250581. eCollection 2020.
10
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.复发性/难治性霍奇金淋巴瘤的治疗效果优化：当前及未来治疗策略综述
Ther Adv Hematol. 2020 Feb 16;11:2040620720902911. doi: 10.1177/2040620720902911. eCollection 2020.
本妥昔单抗维布妥昔单抗联合纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的初步结果。
Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11.
4
Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.采用多维尔标准的自体移植前PET/CT是复发难治性经典型霍奇金淋巴瘤病情进展的独立预测指标。
Bone Marrow Transplant. 2017 Sep;52(9):1342-1344. doi: 10.1038/bmt.2017.143. Epub 2017 Jul 10.
5
Platelets at the interface of thrombosis, inflammation, and cancer.处于血栓形成、炎症和癌症交界处的血小板。
Blood. 2015 Jul 30;126(5):582-8. doi: 10.1182/blood-2014-08-531582. Epub 2015 Jun 24.
6
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.2015年欧洲血液疾病、实体瘤和免疫疾病异基因及自体造血干细胞移植的适应证：当前实践
Bone Marrow Transplant. 2015 Aug;50(8):1037-56. doi: 10.1038/bmt.2015.6. Epub 2015 Mar 23.
7
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.本妥昔单抗维泊妥珠单抗作为自体造血干细胞移植后巩固治疗在有复发或进展风险的霍奇金淋巴瘤患者中的应用（AETHERA）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
8
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.影像学在淋巴瘤分期及疗效评估中的作用：恶性淋巴瘤国际会议影像工作组共识
J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
9
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
10
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.二线挽救化疗用于对含铂一线挽救化疗耐药的适合移植的霍奇金淋巴瘤患者。
Haematologica. 2012 May;97(5):751-7. doi: 10.3324/haematol.2011.047670. Epub 2011 Dec 16.